VBI Vaccines (VBI Vaccines) Retained Earnings : $-582.45 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is VBI Vaccines Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. VBI Vaccines's retained earnings for the quarter that ended in Dec. 2023 was $-582.45 Mil.

VBI Vaccines's quarterly retained earnings declined from Jun. 2023 ($-561.99 Mil) to Sep. 2023 ($-582.43 Mil) and declined from Sep. 2023 ($-582.43 Mil) to Dec. 2023 ($-582.45 Mil).

VBI Vaccines's annual retained earnings declined from Dec. 2021 ($-378.37 Mil) to Dec. 2022 ($-489.61 Mil) and declined from Dec. 2022 ($-489.61 Mil) to Dec. 2023 ($-582.45 Mil).

VBI Vaccines Retained Earnings Historical Data

The historical data trend for VBI Vaccines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VBI Vaccines Retained Earnings Chart

VBI Vaccines Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-262.39

-308.62

-378.37

-489.61

-582.45

VBI Vaccines Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-489.61	-517.36	-561.99	-582.43	-582.45

VBI Vaccines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

VBI Vaccines (OTCPK:SVACD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

VBI Vaccines (VBI Vaccines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (OTCPK:SVACD) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

VBIV:USA LO9A:Germany

Address

160 Second Street, Floor 3, Cambridge, MA, USA, 02142

Website

https://www.vbivaccines.com

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.